Contribution

In this study (https://doi.org/10.1016/j.drup.2024.101068), we found that the CD47/HER2 bispecific antibody can offer a novel therapeutic approach for treating drug-resistant tumors. The authors discovered that many patients develop resistance to Trastuzumab treatment for HER2-positive breast cancer, posing a challenge in clinical therapy. They also found that CD47 expression is upregulated in drug-resistant cancer cells, which is associated with Trastuzumab resistance. Compared to existing monoclonal antibodies, this bispecific antibody treatment holds the potential for higher efficacy and lower off-target toxicity than using a CD47 antibody, a HER2 antibody (Trastuzumab), or their combination alone. This bispecific antibody significantly inhibited tumor growth via enhancing CD11b+ macrophage infiltration in two trastuzumab-resistant HER2+ BC PDX tumor models (Fig.1-2).